AMBER KEENAN: Open Payments
NPI 1972022465 · NAPA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$791 in 32 payments from 12 companies in 2025. Trend: 2023 $949 · 2024 $756 · 2025 $791
Food & beverage: $791
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 12 | $212 |
| CSL Behring | 1 | $114 |
| Genentech USA, Inc. | 3 | $71 |
| GlaxoSmithKline, LLC. | 3 | $68 |
| Regeneron Healthcare Solutions, Inc. | 2 | $58 |
| Novartis Pharmaceuticals Corporation | 2 | $55 |
| Ionis Pharmaceuticals, Inc. | 2 | $54 |
| BioCryst US Sales Co., LLC | 2 | $46 |
| Kowa Pharmaceuticals America, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
Products named: DUPIXENT, Andembry, Xolair, NUCALA, DAWNZERA, ORLADEYO, ZORYVE, CUVITRU.
Industry payments across CA — which companies pay providers there.
